Allodynic Therapeutics, LLC Email Format
Pharmaceutical ManufacturingFlorida, United States2-10 Employees
Allodynic Therapeutics is a clinical-stage biopharmaceutical company developing ALLOD-2, an oral candidate intended for the acute treatment of migraine. The formulation combines naltrexone and acetaminophen, reflecting the idea that each component can influence physical and emotional pain, potentially improving therapeutic outcomes. U.S. patents protect ALLOD-2 through 2037. The company is based in North Miami, Florida, and operates as a small team within the pharmaceutical manufacturing sector. Its focus is early-stage clinical development to offer a new oral option for individuals experiencing migraine attacks.